With the recent FDA approval, Jeuveau execs believe they’ve got a brand that could neutralize the existing monopoly.
Sandoz, a division of Novartis, announced that the U.S. Food and Drug Administration approved its biosimilar, adalimumabadaz (Hyrimoz, Novartis AG).
The U.S. Food and Drug Administration has approved clearance for a new acne treatment that selectively targets sebaceous glands, according to a news release.
The FDA has approved Ortho Dermatologic’s new drug application for Altreno (tretinoin 0.05 percent) lotion for the treatment of acne vulgaris.
Until the approval of Eskata (hydrogen peroxide) for the treatment of raised seborrheic keratosis back in December, there was no FDA-approved treatment for this condition. Learn the latest in this article.
Ortho Dermatologics announced in August that it resubmitted a new drug application to the FDA for DUOBRIITM1, a lotion for the treatment of plaque psoriasis.
In October, the Food and Drug Administratin is expected to decide on the approval of omadacycline (Paratek Pharmaceuticals) for the treatment of acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.
In June, Dermira Inc. announced the FDA approval of Qbrexza (glycopyrronium) for primary axillary hyperhidrosis ― excessive underarm sweating.
Combination that extends survival in BRAF-mutant metastatic melanoma gains FDA approval.
The July issue of Dermatology Times highlights some newly approved treatments in dermatology including a new wrinkle filler and new treatment for seborrheic keratosis.